Molecular targeted therapies for breast cancer treatment

被引：60

作者：

Schlotter, Claus M. ^{[2
]}

Vogt, Ulf ^{[3
]}

Allgayer, Heike ^{[4
]}

Brandt, Burkhard ^{[1
,5
]}

机构：

[1] Univ Med Ctr Hamburg Eppendorf, Inst Tumor Biol, D-20246 Hamburg, Germany

[2] Univ Bonn, Acad Teaching Hosp, Breast Ctr, Klinikum Ludenscheid,Dept Obstet & Gynecol, D-58515 Luedenscheid, Germany

[3] European Lab Assoc, D-49477 Ibbenburen, Germany

[4] Heidelberg Univ, Fac Mannheim, Dept Expt Surg & Mol Oncol, DKFZ, D-68167 Mannheim, Germany

[5] Univ Med Ctr Hamburg Eppendorf, Inst Tumor Biol, D-20246 Hamburg, Germany

来源：

BREAST CANCER RESEARCH | 2008年 / 10卷 / 04期

关键词：

D O I：

10.1186/bcr2112

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

Targeting the oestrogen receptor, HER2 (human epidermal growth factor receptor 2) and vascular endothelial growth factor has markedly improved breast cancer therapy. New targeted therapeutic approaches to induction of apoptosis or inhibition of antiapoptosis, cell cycle progression, signal transduction and angiogenesis are described. The molecular pathways and their inhibitory or repair mechanisms are discussed in the preclinical and clinical settings.

引用

页数：12

共 87 条

[1]

Nuclear factor-κB p65 inhibits mitogen-activated protein kinase signaling pathway in radioresistant breast cancer cells [J].

Ahmed, Kazi M. ;

Dong, Shaozhong ;

Fan, Ming ;

Li, Jian Jian .

MOLECULAR CANCER RESEARCH, 2006, 4 (12) :945-955

[2]

Development of farnesyl transferase inhibitors: A review [J].

Appels, NMGM ;

Beijnen, JH ;

Schellens, JHM .

ONCOLOGIST, 2005, 10 (08) :565-578

[3]

Treatment of human epidermal growth factor receptor 2-overexpressing breast cancer xenografts with multiagent HER-targeted therapy [J].

Arpino, Grazia ;

Gutierrez, Carolina ;

Weiss, Heidi ;

Rimawi, Mothaffar ;

Massarweh, Suleiman ;

Bharwani, Lavina ;

De Placido, Sabino ;

Osborne, C. Kent ;

Schiff, Rachel .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2007, 99 (09) :694-705

[4]

BERNSTEIN JA, 2006, P AN M AM SOC CLIN, V24, pS584

[5]

BRANDT B, 2007, INDIVIDUALIZED CONCE, V4, P55

[6]

The combination of p53 mutation and neu/erbB-2 amplification is associated with poor survival in node-negative breast cancer [J].

Bull, SB ;

Ozcelik, H ;

Pinnaduwage, D ;

Blackstein, ME ;

Sutherland, DAJ ;

Pritchard, KI ;

Tzontcheva, AT ;

Sidlofsky, S ;

Hanna, WM ;

Qizilbash, AH ;

Tweeddale, ME ;

Fine, S ;

McCready, DR ;

Andrulis, IL .

JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (01) :86-96

[7]

Studies of epidermal growth factor receptor inhibition in breast cancer [J].

Bundred, NJ ;

Chan, K ;

Anderson, NG .

[8]

Burstein HJ, 2002, BREAST CANCER RES TR, V76, pS115

[9]

Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: Results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer [J].

Buzdar, AU ;

Ibrahim, NK ;

Francis, D ;

Booser, DJ ;

Thomas, ES ;

Theriault, RL ;

Pusztai, L ;

Green, MC ;

Arun, BK ;

Giordano, SH ;

Cristofanilli, M ;

Frye, DK ;

Smith, TL ;

Hunt, KK ;

Singletary, SE ;

Sahin, AA ;

Ewer, MS ;

Buchholz, TA ;

Berry, D ;

Hortobagyi, GN .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) :3676-3685

[10]

Bortezomib (PS-341, Velcade) increases the efficacy of trastuzumab (Herceptin) in HER-2-positive breast cancer cells in a synergistic manner [J].

Cardoso, Fatima ;

Durbecq, Virginie ;

Laes, Jean-Francois ;

Badran, Bassam ;

Lagneaux, Laurence ;

Bex, Francoise ;

Desmedt, Christine ;

Willard-Gallo, Karen ;

Ross, Jeffrey S. ;

Burny, Arsene ;

Piccart, Martine ;

Sotiriou, Christos .

MOLECULAR CANCER THERAPEUTICS, 2006, 5 (12) :3042-3051

← 1 2 3 4 5 6 7 8 9 →